Login
MacroGenics NASDAQ: MGNX
We are a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, autoimmune disorders and infectious diseases
| Name | MacroGenics |
| Ticker | MGNX |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
|
Price
52W Low/High |
25.78
18.99 / 35.63 |
| Momentum | Neutral |
| Market cap | 1.5 B |
| 1Y Total Return |
2.06 %
Subpar |
| 1Y Volatility |
61.06 %
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
We are a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, autoimmune disorders and infectious diseases
Details
| Ticker | MGNX |
| Name | MacroGenics |
| ISIN | |
| CUSIP | 556099109 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | NASDAQ Biotechnology Index |
Share as of 07/23/2021
| Close Price | 25.78 |
| 52W Low/High | 18.99 / 35.63 |
| Market cap | 1.5 B |
| 1Y Total Return |
2.06 %
Subpar |
| 1Y Volatility |
61.06 %
High Risk |
| Beta | 2.03 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -126.1 % |
| Cash from Op. / Cur. Liabilities | -1.82 |
| Diluted Earnings / Share | -2.48 |
| ROE | - |
| ROIC | -91.9 % |
| Price / Revenue | 13.6 |
| Price / Book | 4.2 |
| Price / CF | -15.2 |
| Current Ratio | 7.1 |
| Cur.Liabilities / Tot.Liabilities | 0.6 |
| Financial Leverage | 0.08 |
| in Mils USD |
rolling-year up to March
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Revenue |
108
|
68
|
65
|
160
|
91
|
32
|
|
| Gross Profit |
108
|
68
|
65
|
160
|
91
|
32
|
|
| R&D |
197
|
197
|
192
|
160
|
128
|
104
|
|
| EBITDA |
-124
|
-139
|
-156
|
-25
|
-58
|
-92
|
|
| Operating Income |
-137
|
-175
|
-169
|
-34
|
-68
|
-96
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
57
|
49
|
46
|
37
|
35
|
35
|
|
| EPS exc. Extra |
-2.48
|
-3.09
|
-3.89
|
-0.80
|
-1.93
|
-2.93
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Total Assets |
435
|
265
|
415
|
326
|
275
|
326
|
|
| Cash, Eq & Invt ShortTerm |
343
|
171
|
320
|
260
|
243
|
304
|
|
| Total Current Assets |
375
|
195
|
335
|
271
|
251
|
309
|
|
| Total Non-Current Assets |
61
|
70
|
80
|
55
|
24
|
16
|
|
| Intangibles |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
85
|
75
|
94
|
79
|
40
|
39
|
|
| Total Current Liabilities |
53
|
40
|
52
|
50
|
27
|
18
|
|
| Long Term Debt |
32
|
35
|
42
|
29
|
14
|
22
|
|
| Shareholder equity |
351
|
191
|
321
|
247
|
235
|
286
|
|
| Cash Flow | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Cash from Operations |
-97
|
-148
|
-152
|
18
|
-47
|
-89
|
|
| Depreciation |
12
|
12
|
11
|
7
|
8
|
4
|
|
| Cash from Investing |
-53
|
2
|
-33
|
106
|
-66
|
-164
|
|
| Capex |
5
|
4
|
12
|
42
|
10
|
11
|
|
| Cash from Financing |
275
|
1
|
223
|
36
|
2
|
142
|
|
| Stock Issued |
275
|
1
|
223
|
36
|
2
|
142
|
|
| Debt (LT) Issued |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Free Cash Flow |
-173
|
-157
|
-228
|
140
|
-121
|
-248
|
|
| Ratios | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
7.1
|
4.9
|
6.5
|
5.4
|
9.5
|
17.4
|
|
| Financial Leverage D/E |
0.08
|
0.16
|
0.09
|
0.00
|
0.00
|
0.00
|
|
| Return on Capital Avg |
-91.9 %
|
-117.9 %
|
-167.0 %
|
-22.2 %
|
-36.2 %
|
-130.6 %
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available